KOL Views: Melanoma in focus – how are MEK/BRAF combos faring in post-I/O universe and where might Array’s bini/enco fit within that

Array BioPharma reported encouraging top-line data this month from a Phase III trial of binimetinib plus encorafenib (bini/enco) to treat advanced melanoma that the company said will support an NDA filing this summer. With two competing MEK/BRAF inhibitor combinations on the market in this setting, which is also being transformed by immuno-oncology drugs, commercial uptake of Array’s offering is no sure thing.

To provide FirstWord readers with a better understanding of how MEK/BRAF prescribing patterns are evolving and what the market opportunity is for Array’s bini/enco, we are hosting an expert call with a key opinion leader on May 19.

Key topics that will be discussed during the call include, among other things… in what line(s) of therapy do you consider using a MEK/BRAF combo, and what factors determine prescribing decisions; how has the availability of I/O options changed utilisation of MEK/BRAF combos, and how is this likely to evolve in the near- and longer-term; what are the most notable shortcomings of MEK/BRAF combos marketed by Novartis and Roche; how do the bini/enco Phase III data compare to the more established offerings, how might Array differentiate bini/enco, and what are your expectations for how much use it is likely to receive?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the MEK/BRAF treatment landscape.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.